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ABSTRACT
Measures to alleviate the growing problem of
macrolide resistance in Taiwan resulted in a
decrease in macrolide consumption, from 0.629
defined daily doses ⁄ 1000 inhabitants per day
(DIDs) in 1999 to 0.301 DIDs in 2003 (a reduction
of 52%). A linear relationship was observed
between the decline in erythromycin con-
sumption and the decline in erythromycin resist-
ance in Streptococcus pyogenes (46% in 1999 vs.
17% in 2003; p < 0.001) and azithromycin resis-
tance in Haemophilus influenzae (31% in 2000 vs.
0% in 2003; p < 0.001). However, the rate of
erythromycin resistance in Streptococcus pneumo-
niae showed a continued increase, from 80.2% in
1999 to 92% in 2003.
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Taiwan has one of the highest levels of antimi-
crobial resistance in the world [1]. In particular,
the resistance of respiratory pathogens (Strepto-
coccus pyogenes, Streptococcus pneumoniae and
Haemophilus influenzae) to macrolides is of great
concern, since several guidelines recommend
macrolides as drugs of choice for community-
acquired respiratory tract infections caused by
these organisms. Prior to 2000, rates of macrolide
resistance in S. pneumoniae (80–90%) and S. pyo-
genes (40–70%), and of azithromycin resistance in
H. influenzae (30–50%), were remarkably high
[1–3]. A number of measures were taken to
alleviate this growing problem, including rigor-
ous enforcement of prescription completion in
pharmacies, and educational programmes for
physicians that focused on appropriate antibiotic
use. In addition, a restrictive governmental policy
was implemented in 2001 to deny reimbursement
through the National Health Insurance system for
the costs of antibiotics used for the treatment of
acute upper respiratory tract infections without
evidence of bacterial involvement [4].
To assess the relationship between macrolide
consumption and macrolide resistance in the
three pathogens mentioned above, data concern-
ing the annual consumption of macrolides (ex-
pressed as defined daily doses ⁄ 1000 inhabitants
per day; DIDs) obtained from IMS Health (Inter-
continental Marketing Service, Taipei, Taiwan)
were evaluated [4]. Pooled disk-diffusion sus-
ceptibility data concerning erythromycin resist-
ance in 3677 isolates of S. pneumoniae (collected
between 1999 and 2003) and 1170 S. pyogenes
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isolates (1999–2003), and azithromycin resistance
in 724 H. influenzae isolates (2000–2003), from
three major teaching hospitals in Taiwan were
analysed according to NCCLS guidelines [5]. The
three hospitals were the National Taiwan Univer-
sity Hospital (2000 beds), Taichung Veterans
General Hospital (1400) and National Cheng-
Kung University Hospital (1800). Disk suscepti-
bility testing of erythromycin, as well as
determination of erythromycin-resistant pheno-
types using the double-disk method, were also
performed on 241 S. pyogenes isolates collected
from 15 major teaching hospitals in Taiwan
between January and April 2004 (Surveillance of
Multicentre Antimicrobial Resistance in Taiwan
(SMART) 2004 programme) [5,6].
The consumption of macrolides decreased from
0.629 DIDs in 1999 to 0.301 DIDs in 2003 (a
reduction of 52%) [4]. Following implementation
of the restrictive antibiotic reimbursement policy,
a stepwise reduction in erythromycin consump-
tion was observed between 2000 (0.447 DIDs) and
2003 (0.129 DIDs) (Fig. 1) [4]. A slight increase
(0.033 DIDs in 2000 to 0.035 DIDs in 2003) in
azithromycin consumption was noted, although
consumption declined in both 2001 and 2002.
The use of clarithromycin and roxithromycin
increased between 1999 (0.127 DIDs) and 2002
(0.216 DIDs), but declined in 2003 (0.137 DIDs). A
linear relationship was observed between the
decline in erythromycin consumption and the
decline in rates of erythromycin resistance in
S. pyogenes (46% in 1999 vs. 17% in 2003; Pear-
son’s correlation coefficient, r = 0.943, p < 0.001)
and azithromycin resistance in H. influenzae (31%
in 2000 vs. 0% in 2003; r = 0.926, p < 0.001).
However, the rate of erythromycin resistance in
S. pneumoniae showed a continued increase from
80.2% in 1999 to 92% in 2003. A low (12%) rate
of erythromycin resistance was also found in
isolates from the nationwide SMART S. pyogenes
collection in 2004. Among the 29 erythromycin-
resistant isolates, 26 (90%) possessed the M
phenotype.
The present results, showing that a reduction in
erythromycin use was followed by a decline in
macrolide resistance in S. pyogenes and H. influ-
enzae, but not in S. pneumoniae, expand previous
findings [4,6–8]. The substantial upsurge in the
incidence of isolates of S. pyogenes with the
M phenotype (low-level resistance efflux mech-
anism) during the past few years was associated
with increasing susceptibility of this organism to
erythromycin [6]. However, a similar M pheno-
type distribution was not found in S. pneumoniae
[6]. Disappearance of one or more clones of highly
erythromycin-resistant S. pyogenes in the commu-
nity might account for the overall reduction in
resistance [9,10].
In Taiwan, > 60% of erythromycin-resistant
S. pneumoniae isolates were also resistant to peni-
cillin, tetracycline and trimethoprim–sulphameth-
oxazole (multidrug-resistant isolates) [3,11,12].
Among H. influenzae isolates, > 40% were insus-
ceptible to trimethoprim–sulphamethoxazole,
25% were insusceptible to chloramphenicol, and
> 50% produced a b-lactamase [3]. The increase in
macrolide resistance among S. pneumoniae isolates
might be associated with selection of multiresist-
ant strains by other classes of antimicrobial agent
[13]. In the USA, decreased use of non-fluoroqu-
inolone antibiotics has led to decreased rates of
resistance to fluoroquinolones in S. pneumoniae
[14]. However, in Taiwan, a reduction in con-
sumption of penicillins and cephalosporins
(15.7 DIDs in 1999 vs. 8.5 DIDs in 2001), trimeth-
oprim and sulphonamides (1.9 DIDs in 1999 vs.
1.6 DIDs in 2001) and tetracyclines (3.9 DIDs in
1999 vs. 3.0 DIDs in 2001) was found in ambula-
tory patients [15]. The reasons for the discordant
selection of macrolide resistance among these
three respiratory tract pathogens remain unclear
and need further investigation.
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Fig. 1. Relationship between macrolide consumption (de-
fined daily doses ⁄ 1000 inhabitants per day; DIDs) and
erythromycin resistance among isolates of Streptococcus
pyogenes (1999–2003) and Streptococcus pneumoniae (1999–
2003), and azithromycin resistance among isolates of
Haemophilus influenzae (2000–2003), obtained from patients
treated at three major hospitals in Taiwan.
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The rate at which resistance declines following
a reduction in antibiotic use seems to vary with
different species of bacteria. More time is required
to determine the eventual overall impact of
reduced macrolide consumption on macrolide
resistance in S. pneumoniae. Appropriate use of
antimicrobial agents appears to be the cornerstone
for limiting the emergence and spread of
drug-resistant bacteria. Routine nationwide sur-
veillance of resistance trends and continued
adherence to government policies designed to
limit unnecessary use of antimicrobial agents are
warranted.
REFERENCES
1. Hsueh PR, Liu CY, Luh KT. Current status of antimicro-
bial resistance in Taiwan. Emerg Infect Dis 2002; 8: 132–137.
2. Hsueh PR, Chen HM, Huang AH, Wu JJ. Decreased
activity of erythromycin against Streptococcus pyogenes in
Taiwan. Antimicrob Agents Chemother 1995; 39: 2239–2242.
3. Hsueh PR, Liu YC, Shyr JM et al. Multicenter surveillance
of antimicrobial resistance of Streptococcus pneumoniae,
Haemophilus influenzae, and Moraxella catarrhalis in Taiwan
during the 1998–1999 respiratory season. Antimicrob
Agents Chemother 2000; 44: 1342–1345.
4. Hsueh PR, Shyr JM, Wu JJ. Decreased erythromycin use
after antimicrobial reimbursement restriction for undocu-
mented bacterial upper respiratory tract infections signi-
ficantly reduced erythromycin resistance in Streptococcus
pyogenes in Taiwan. Clin Infect Dis 2005; 15: 903–905.
5. National Committee for Clinical Laboratory Standards.
Performance standards for antimicrobial disk susceptibility
tests, 8th edn. Approved standard M2-A8. Wayne, PA:
NCCLS, 2003.
6. Hsueh PR, Teng LJ, Lee NL et al. Extremely high propor-
tion and substantial upsurge in incidence of erythromycin-
resistant M phenotype in Streptococcus pyogenes but not in
Streptococcus pneumoniae isolates collected over a 15-year
period in Taiwan. Microb Drug Resist 2002; 8: 27–33.
7. Seppala H, Klaukka T, Vupio-Varkila J et al. The effect of
changes in the consumption of macrolide antibiotics on
erythromycin resistance in group A streptococci in Fin-
land. Finnish Study Group for Antimicrobial Resistance.
N Engl J Med 1997; 337: 491–492.
8. Bergman M, Huikko S, Pihlajamaki M et al. Effect of
macrolide consumption on erythromycin resistance in
Streptococcus pyogenes in Finland in 1997–2001. Clin Infect
Dis 2004; 38: 1251–1256.
9. Martin JM, Green M, Barbadora KA, Wald ER. Erythro-
mycin-resistant group A streptococci in schoolchildren in
Pittsburgh. N Engl J Med 2002; 346: 1200–1206.
10. Yan JJ, Wu HM, Huang AH, Fu HM, Lee CT, Wu JJ. Pre-
valence of polyclonal mefA-containing isolates among
erythromycin-resistant group A streptococci in Southern
Taiwan. J Clin Microbiol 2000; 38: 2475–2479.
11. Hsueh PR, Teng LJ, Wu TL et al. Telithromycin- and
fluoroquinolone-resistant Streptococcus pneumoniae in
Taiwan with high prevalence of resistance to macrolides
and beta-lactams: SMART Program 2001 data. Antimicrob
Agents Chemother 2003; 47: 2145–2151.
12. Hsueh PR, Luh KT. Antimicrobial resistance in Strepto-
coccus pneumoniae, Taiwan. Emerg Infect Dis 2002; 8: 1487–
1491.
13. Farrell DJ, Jenkins SG, Brown SD, Patel M, Lavin BS,
Klugman KP. Emergence and spread of Streptococcus
pneumoniae with erm(B) and mef(A) resistance. Emerg Infect
Dis 2005; 11: 851–858.
14. Doern GV, Richter SS, Miller A et al. Antimicrobial
resistance among Streptococcus pneumoniae in the United
States: have we begun to turn the corner on resistance to
certain antimicrobial classes? Clin Infect Dis 2005; 41: 139–
148.
15. Ho M, Hsiung CA, Yu HT, Chi CL, Chang HJ. Changes
before and after a policy to restrict antimicrobial usage in
upper respiratory tract infections in Taiwan. Int J Anti-
microb Agents 2004; 23: 438–445.
298 Clinical Microbiology and Infection, Volume 12 Number 3, March 2006
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 12, 285–298
